Healthcare [ 6/11 ] | Biotechnology [ 76/148 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 3, 23 | 0.43 Increased by +191.49% | 0.50 Decreased by -14.00% |
| May 4, 23 | -0.53 Increased by +36.90% | -0.49 Decreased by -8.16% |
| Mar 9, 23 | -0.51 Increased by +42.70% | -0.47 Decreased by -8.51% |
| Nov 2, 22 | -0.44 Increased by +43.59% | -0.58 Increased by +24.14% |
| Aug 4, 22 | -0.47 Increased by +40.51% | -0.67 Increased by +29.85% |
| May 4, 22 | -0.84 Decreased by -13.51% | -0.73 Decreased by -15.07% |
| Mar 10, 22 | -0.89 Increased by +18.35% | -0.83 Decreased by -7.23% |
| Nov 4, 21 | -0.78 Increased by +92.91% | -0.81 Increased by +3.70% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 6.89 M Increased by +86.46% | -18.79 M Increased by +5.69% | Decreased by -272.89% Increased by +49.42% |
| Mar 31, 23 | 2.72 M Increased by +5.91% | -22.95 M Increased by +35.55% | Decreased by -843.00% Increased by +39.14% |
| Dec 31, 22 | 3.54 M Increased by +863.76% | -21.89 M Increased by +41.97% | Decreased by -618.77% Increased by +93.98% |
| Sep 30, 22 | 4.11 M Increased by +167.14% | -18.62 M Increased by +43.78% | Decreased by -453.51% Increased by +78.96% |
| Jun 30, 22 | 3.69 M Increased by +139.03% | -19.92 M Increased by +33.18% | Decreased by -539.51% Increased by +72.05% |
| Mar 31, 22 | 2.57 M Increased by +182.53% | -35.62 M Decreased by -28.69% | Decreased by -1.39 K% Increased by +54.45% |
| Dec 31, 21 | 367.00 K Increased by +N/A% | -37.71 M Decreased by -9.57% | Decreased by -10.28 K% Decreased by N/A% |
| Sep 30, 21 | 1.54 M Increased by +N/A% | -33.12 M Increased by +0.52% | Decreased by -2.16 K% Decreased by N/A% |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.